Nimenrix meningitis vaccine edges closer to the market for GSK

The European Medicines Agency has recommended approval for GlaxoSmithKline's ($GSK) conjugate vaccine against meningococcal disease in adults and children from the age of 12 months. The active vaccine targets Neisseria meningitidis groups A, C, W-135 and Y. The Committee for Medicinal Products for Human Use (CHMP) said it "considers there to be a favorable benefit-to-risk balance for Nimenrix and therefore recommends the granting of the marketing authorization." Thomas Breuer, senior vice president and head of global vaccine development at GSK, commented: "GSK has over 20 years experience in developing meningococcal vaccines. This positive opinion represents a major milestone in our development program and we look forward to receiving the final decision from the EMA in the coming months." Press release | EMA summary (.pdf)

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.